Paris – After lagging the vaccine race, Sanofi and GlaxoSmithKline finally claimed on Wednesday that their single Covid vaccine booster shot strengthens the immune system against the virus, the preliminary results of the clinical trials revealed.

The British and French partners said they expect more Phase III stage study outcomes of their Covid 19 vaccine shot in the first half of 2022.

After the current results, the companies plan to file their vaccine data with the authorities.

In a recent statement, the companies said, “The booster was well tolerated, with a safety profile similar to currently approved Covid-19 vaccines. This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination.”

“To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022.”

For the booster shot, the company has used a similar technology that it had used for the influenza vaccine and an adjuvant, a drug used to increase the potency of some drugs.

After lagging in the race of producing vaccines for Covid, the company has spread optimism across the industry with their booster shot news.

The previous year, the vaccine provided insufficient immunity against covid for people aged 60 and more. However, the companies were optimistic that they would work on it and launch it in the first half of the current year.

Later in September, the company dropped its plan to introduce its very own mRNA-based COVID-19 vaccine as Moderna and  BioNTech-Pfizer already dominated the market.

The booster shot that was tested on different demographics, including the people age 60 and above, can be given to all those who have received Johnson & Johnson, Pfizer/BioNTech, AstraZeneca and Moderna Covid 19 vaccines.

It was examined in the period of four to ten months following a complete schedule for the primary vaccine for Covid-19 when the Omicron variant had not emerged. “Preliminary results from the VAT0002 clinical trial investigating the safety and immunogenicity of the booster showed neutralizing antibodies increased nine to 43-fold regardless of the primary vaccine received (AstraZeneca, Johnson & Johnson, Moderna, Pfizer/BioNTech) and for all age groups tested”, said the Paris based pharma company, Sanofi.